Eli Lilly has agreed a deal to acquire French antibody-drug conjugate (ADC) specialist Mablink, continuing a series of transactions that build its position in what has become one of the ...
Adcendo has tapped into the strong investor appetite for companies developing antibody-drug conjugates for cancer with an oversubscribed second round that raised $135 million. The Copenhagen, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback